Canatu Oyj（0CD）株式概要Canatu Oyj社は、フィンランド、米国、日本、台湾において、半導体、自動車、医療診断業界向けにカーボンナノチューブ（CNT）および関連製品を開発・販売している。 詳細0CD ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長5/6過去の実績0/6財務の健全性4/6配当金0/6報酬当社が推定した公正価値より39.7%で取引されている 収益は年間59.68%増加すると予測されています 過去 1 年間で収益は406.1%増加しましたリスク分析German市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る0CD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€9.0012.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-10m66m2016201920222025202620282031Revenue €65.8mEarnings €10.4mAdvancedSet Fair ValueView all narrativesCanatu Oyj 競合他社centrotherm internationalSymbol: DB:CTNKMarket cap: €190.5mPVA TePlaSymbol: XTRA:TPEMarket cap: €950.0mELES Semiconductor EquipmentSymbol: DB:1EPMarket cap: €56.2mSUSS MicroTecSymbol: XTRA:SMHNMarket cap: €1.7b価格と性能株価の高値、安値、推移の概要Canatu Oyj過去の株価現在の株価€9.0052週高値€11.3552週安値€6.70ベータ0.511ヶ月の変化15.98%3ヶ月変化-2.39%1年変化n/a3年間の変化-10.00%5年間の変化n/aIPOからの変化-19.04%最新ニュースBoard Change • May 21Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Tuomo Vahapassi is the most experienced director on the board, commencing their role in 2024. Independent Director Bernhard Stockmeyer was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 17Canatu Oyj Elects Anette Engelhardt as Member of the BoardCanatu Plc at its Annual General Meeting held on April 16, 2026 announced the election of Anette Engelhardt as a new member of the Board of the Directors until the end of the next Annual General Meeting.お知らせ • Feb 11Canatu plc Appoints Antti Härmänmaa as Vice President, Legal and General Counsel, and Member of the Leadership Team, Effective 9 February 2026Canatu Plc has appointed Antti Härmänmaa as Vice President, Legal and General Counsel, and a member of the Leadership Team, effective 9 February 2026. The role is newly established and introduces Canatu's in-house legal function. In his role, Antti Härmänmaa is responsible for creating and leading Canatu's in-house legal function and providing legal counsel across the organization. His responsibilities cover legal, compliance, corporate governance, intellectual property rights, and contract matters. He will report to CEO Juha Kokkonen. Antti Härmänmaa (LL.M., Helsinki, New York University; eMBA, Aalto; b. 1979) brings extensive experience from senior legal leadership roles in international technology and media companies. He joins Canatu from Nokia Technologies, where he most recently served as Head of IP Legal and IP Business Services (2024-2026), following his role as Director, Legal & Compliance (2023-2024). Previously, Härmänmaa held senior legal leadership roles at Teosto (2017-2021) and at Sanoma (2008-2017). In addition, he serves as an Expert Member of the Market Court of Finland.お知らせ • Jan 07Canatu Plc Announces Composition Of Shareholders' Nomination BoardCanatu Plc announced the composition of its Shareholders’ Nomination Board. The members of Canatu Plc’s Shareholders’ Nomination Board have been appointed. The composition of the Shareholders’ Nomination Board is the following: Ari Ahola (appointed by eFruit International Inc.), Denis Cherkasov (appointed by Mymetics Holding (Cyprus) Limited), Shinichiro Nakamura (appointed by DENSO Corporation), Tuomo Vähäpassi (appointed by Inventure Fund Ky). The Nomination Board elected Ari Ahola as Chair from among its members. In accordance with the Charter of the Shareholders’ Nomination Board, the Shareholders’ Nomination Board consists of four members, representing Canatu’s four largest shareholders, who held the largest number of votes in Canatu based on the shareholders’ register as per the situation on the first banking day of October 2025, considering the nominee-registered shares, and exercised their right of appointment. As the fourth largest shareholder Varma Mutual Pension Insurance Company did not exercise its right of appointment, the right was transferred to the fifth largest shareholder in accordance with the Charter of the Shareholders’ Nomination Board, Inventure Fund Ky, which appointed the fourth member of the Shareholder’s Nomination Board. The Chair of Canatu’s Board of Directors participates in the Shareholders’ Nomination Board’s work as an expert without having a right to participate in the decision-making of the Shareholders’ Nomination Board. The Shareholders’ Nomination Board is a corporate body appointed by Canatu’s shareholders that is responsible for preparing proposals to the annual general meeting, and if necessary, to the extraordinary general meeting, on the number, election, and remuneration of the members of the Board of Directors.お知らせ • Aug 29+ 2 more updatesCanatu Oyj, Annual General Meeting, Apr 16, 2026Canatu Oyj, Annual General Meeting, Apr 16, 2026.お知らせ • Jul 11Canatu plc Receives Customer Approval for its CNT100 SEMI Receptor and Post-Processing Equipment, Enabling Mass Production of Advanced EUV PelliclesCanatu Plc has received Site Acceptance Test (SAT) approval for its first CNT100 SEMI reactor and for the related post-processing peripherals, shipped to a semiconductor customer in September 2024. The equipment successfully passed the extensive tests conducted on-site at the customer's premises and met the stringent technical requirements and specifications defined in the acceptance criteria. This confirms the CNT100 SEMI reactor's readiness for mass production of CNT pellicle membranes. The next step for the customer is to secure final approval for the ready CNT pellicle product and the complete manufacturing line, before pilot and risk mass production can begin. This phase would initiate the mass production of CNT peLLicle membranes, generating non-recurring revenue from technology licensing, as well as recurring revenue from royalties on CNT pellicle sales, and from reactor consumables. Site Acceptance Test (Sat) means that the equipment is tested on-site after Factory Acceptance Test (FAT) to ensure the reactor and peripherals operate as intended in real use conditions. The SAT process included several output and product quality tests. With the SAT approval, Canatu's CNT100 SEMI reactor & peripherals are now ready for mass production. Demand for advanced semiconductors is accelerating due to the rapid growth of artificial intelligence. EUV (Extreme Ultraviolet) lithography is gaining traction, especially for sub-7 nanometer chips--the fastest-growing segment. Canatu is well-positioned to support this shift with its advanced CNT pellicle membranes, which perform traditional composite pellicles. These membranes offer higher EUV transmission and greater thermal resistance, enabling them to withstand the extreme heat loads of 600W EUV lithography tools used to produce the most advanced chips.最新情報をもっと見るRecent updatesBoard Change • May 21Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Tuomo Vahapassi is the most experienced director on the board, commencing their role in 2024. Independent Director Bernhard Stockmeyer was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Apr 17Canatu Oyj Elects Anette Engelhardt as Member of the BoardCanatu Plc at its Annual General Meeting held on April 16, 2026 announced the election of Anette Engelhardt as a new member of the Board of the Directors until the end of the next Annual General Meeting.お知らせ • Feb 11Canatu plc Appoints Antti Härmänmaa as Vice President, Legal and General Counsel, and Member of the Leadership Team, Effective 9 February 2026Canatu Plc has appointed Antti Härmänmaa as Vice President, Legal and General Counsel, and a member of the Leadership Team, effective 9 February 2026. The role is newly established and introduces Canatu's in-house legal function. In his role, Antti Härmänmaa is responsible for creating and leading Canatu's in-house legal function and providing legal counsel across the organization. His responsibilities cover legal, compliance, corporate governance, intellectual property rights, and contract matters. He will report to CEO Juha Kokkonen. Antti Härmänmaa (LL.M., Helsinki, New York University; eMBA, Aalto; b. 1979) brings extensive experience from senior legal leadership roles in international technology and media companies. He joins Canatu from Nokia Technologies, where he most recently served as Head of IP Legal and IP Business Services (2024-2026), following his role as Director, Legal & Compliance (2023-2024). Previously, Härmänmaa held senior legal leadership roles at Teosto (2017-2021) and at Sanoma (2008-2017). In addition, he serves as an Expert Member of the Market Court of Finland.お知らせ • Jan 07Canatu Plc Announces Composition Of Shareholders' Nomination BoardCanatu Plc announced the composition of its Shareholders’ Nomination Board. The members of Canatu Plc’s Shareholders’ Nomination Board have been appointed. The composition of the Shareholders’ Nomination Board is the following: Ari Ahola (appointed by eFruit International Inc.), Denis Cherkasov (appointed by Mymetics Holding (Cyprus) Limited), Shinichiro Nakamura (appointed by DENSO Corporation), Tuomo Vähäpassi (appointed by Inventure Fund Ky). The Nomination Board elected Ari Ahola as Chair from among its members. In accordance with the Charter of the Shareholders’ Nomination Board, the Shareholders’ Nomination Board consists of four members, representing Canatu’s four largest shareholders, who held the largest number of votes in Canatu based on the shareholders’ register as per the situation on the first banking day of October 2025, considering the nominee-registered shares, and exercised their right of appointment. As the fourth largest shareholder Varma Mutual Pension Insurance Company did not exercise its right of appointment, the right was transferred to the fifth largest shareholder in accordance with the Charter of the Shareholders’ Nomination Board, Inventure Fund Ky, which appointed the fourth member of the Shareholder’s Nomination Board. The Chair of Canatu’s Board of Directors participates in the Shareholders’ Nomination Board’s work as an expert without having a right to participate in the decision-making of the Shareholders’ Nomination Board. The Shareholders’ Nomination Board is a corporate body appointed by Canatu’s shareholders that is responsible for preparing proposals to the annual general meeting, and if necessary, to the extraordinary general meeting, on the number, election, and remuneration of the members of the Board of Directors.お知らせ • Aug 29+ 2 more updatesCanatu Oyj, Annual General Meeting, Apr 16, 2026Canatu Oyj, Annual General Meeting, Apr 16, 2026.お知らせ • Jul 11Canatu plc Receives Customer Approval for its CNT100 SEMI Receptor and Post-Processing Equipment, Enabling Mass Production of Advanced EUV PelliclesCanatu Plc has received Site Acceptance Test (SAT) approval for its first CNT100 SEMI reactor and for the related post-processing peripherals, shipped to a semiconductor customer in September 2024. The equipment successfully passed the extensive tests conducted on-site at the customer's premises and met the stringent technical requirements and specifications defined in the acceptance criteria. This confirms the CNT100 SEMI reactor's readiness for mass production of CNT pellicle membranes. The next step for the customer is to secure final approval for the ready CNT pellicle product and the complete manufacturing line, before pilot and risk mass production can begin. This phase would initiate the mass production of CNT peLLicle membranes, generating non-recurring revenue from technology licensing, as well as recurring revenue from royalties on CNT pellicle sales, and from reactor consumables. Site Acceptance Test (Sat) means that the equipment is tested on-site after Factory Acceptance Test (FAT) to ensure the reactor and peripherals operate as intended in real use conditions. The SAT process included several output and product quality tests. With the SAT approval, Canatu's CNT100 SEMI reactor & peripherals are now ready for mass production. Demand for advanced semiconductors is accelerating due to the rapid growth of artificial intelligence. EUV (Extreme Ultraviolet) lithography is gaining traction, especially for sub-7 nanometer chips--the fastest-growing segment. Canatu is well-positioned to support this shift with its advanced CNT pellicle membranes, which perform traditional composite pellicles. These membranes offer higher EUV transmission and greater thermal resistance, enabling them to withstand the extreme heat loads of 600W EUV lithography tools used to produce the most advanced chips.お知らせ • Jun 09+ 1 more updateCanatu plc Appoints Nedal Safwat as Chief Development Officer, and President of Canatu Inc, Effective June 9, 2025Canatu Plc announced the appointment of Dr. Nedal Safwat (PhD in Biochemistry) as Chief Development Officer, effective June 9, 2025. In his new role, Dr. Safwat will lead Canatu’s Medical Diagnostics business unit and serve as a member of the Management Team. Dr. Safwat brings over 20 years of industry expertise in medical diagnostics and a strong track record in business development across leading global organizations. Most recently, he served as Vice President, Portfolio and Program Management Office at Cepheid (2025). Before that, he served as the Vice President, Head of Molecular Diagnostics Sales and Marketing – North America at QIAGEN (2021–2024), and Vice President, Marketing and Business Development at ChromaCode Inc. (2020–2021). He also held multiple leadership roles in product development and commercial functions at bioMérieux (2009–2020).株主還元0CDDE SemiconductorDE 市場7D19.0%12.3%1.6%1Yn/a131.8%2.2%株主還元を見る業界別リターン: 0CDがGerman Semiconductor業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 0CD German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 0CD's price volatile compared to industry and market?0CD volatility0CD Average Weekly Movement12.8%Semiconductor Industry Average Movement9.1%Market Average Movement6.0%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: 0CDの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 0CDの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2004181Maximilian Slawinskiwww.canatu.comCanatu Oyj社は、フィンランド、米国、日本、台湾において、半導体、自動車、医療診断業界向けにカーボンナノチューブ（CNT）および関連製品を開発・販売している。同社は、カスタムCNT合成リアクター、高出力EUVリソグラフィーおよびX線フィルター用途のCNT膜、EUVの高透過率を可能にしながらフォトマスクを汚染から保護するEUVペリシー、X線フィルター用途の光学フィルター、EUV光源および光路からゴミをフィルターすることで品質管理を強化する検査膜を提供している。また、フィルム、先進運転支援システム（ADAS）のLIDAR、ADASカメラ、ヘッドライトヒーター、3Dタッチセンサー、電気化学バイオセンサー、電気化学センサーも提供している。Canatu Oyjは2004年に設立され、フィンランドのヴァンターに本社を置いている。もっと見るCanatu Oyj 基礎のまとめCanatu Oyj の収益と売上を時価総額と比較するとどうか。0CD 基礎統計学時価総額€313.31m収益（TTM）-€9.70m売上高(TTM)€16.70m18.8xP/Sレシオ-32.3xPER（株価収益率0CD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計0CD 損益計算書（TTM）収益€16.70m売上原価€3.50m売上総利益€13.20mその他の費用€22.90m収益-€9.70m直近の収益報告Dec 31, 2025次回決算日Aug 25, 2026一株当たり利益（EPS）-0.28グロス・マージン79.04%純利益率-58.08%有利子負債／自己資本比率2.0%0CD の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 10:44終値2026/05/27 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Canatu Oyj 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Waltteri RossiDanske BankMatti RiikonenDNB CarnegieMarianne PalmuInderes Oy2 その他のアナリストを表示
Board Change • May 21Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Tuomo Vahapassi is the most experienced director on the board, commencing their role in 2024. Independent Director Bernhard Stockmeyer was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 17Canatu Oyj Elects Anette Engelhardt as Member of the BoardCanatu Plc at its Annual General Meeting held on April 16, 2026 announced the election of Anette Engelhardt as a new member of the Board of the Directors until the end of the next Annual General Meeting.
お知らせ • Feb 11Canatu plc Appoints Antti Härmänmaa as Vice President, Legal and General Counsel, and Member of the Leadership Team, Effective 9 February 2026Canatu Plc has appointed Antti Härmänmaa as Vice President, Legal and General Counsel, and a member of the Leadership Team, effective 9 February 2026. The role is newly established and introduces Canatu's in-house legal function. In his role, Antti Härmänmaa is responsible for creating and leading Canatu's in-house legal function and providing legal counsel across the organization. His responsibilities cover legal, compliance, corporate governance, intellectual property rights, and contract matters. He will report to CEO Juha Kokkonen. Antti Härmänmaa (LL.M., Helsinki, New York University; eMBA, Aalto; b. 1979) brings extensive experience from senior legal leadership roles in international technology and media companies. He joins Canatu from Nokia Technologies, where he most recently served as Head of IP Legal and IP Business Services (2024-2026), following his role as Director, Legal & Compliance (2023-2024). Previously, Härmänmaa held senior legal leadership roles at Teosto (2017-2021) and at Sanoma (2008-2017). In addition, he serves as an Expert Member of the Market Court of Finland.
お知らせ • Jan 07Canatu Plc Announces Composition Of Shareholders' Nomination BoardCanatu Plc announced the composition of its Shareholders’ Nomination Board. The members of Canatu Plc’s Shareholders’ Nomination Board have been appointed. The composition of the Shareholders’ Nomination Board is the following: Ari Ahola (appointed by eFruit International Inc.), Denis Cherkasov (appointed by Mymetics Holding (Cyprus) Limited), Shinichiro Nakamura (appointed by DENSO Corporation), Tuomo Vähäpassi (appointed by Inventure Fund Ky). The Nomination Board elected Ari Ahola as Chair from among its members. In accordance with the Charter of the Shareholders’ Nomination Board, the Shareholders’ Nomination Board consists of four members, representing Canatu’s four largest shareholders, who held the largest number of votes in Canatu based on the shareholders’ register as per the situation on the first banking day of October 2025, considering the nominee-registered shares, and exercised their right of appointment. As the fourth largest shareholder Varma Mutual Pension Insurance Company did not exercise its right of appointment, the right was transferred to the fifth largest shareholder in accordance with the Charter of the Shareholders’ Nomination Board, Inventure Fund Ky, which appointed the fourth member of the Shareholder’s Nomination Board. The Chair of Canatu’s Board of Directors participates in the Shareholders’ Nomination Board’s work as an expert without having a right to participate in the decision-making of the Shareholders’ Nomination Board. The Shareholders’ Nomination Board is a corporate body appointed by Canatu’s shareholders that is responsible for preparing proposals to the annual general meeting, and if necessary, to the extraordinary general meeting, on the number, election, and remuneration of the members of the Board of Directors.
お知らせ • Aug 29+ 2 more updatesCanatu Oyj, Annual General Meeting, Apr 16, 2026Canatu Oyj, Annual General Meeting, Apr 16, 2026.
お知らせ • Jul 11Canatu plc Receives Customer Approval for its CNT100 SEMI Receptor and Post-Processing Equipment, Enabling Mass Production of Advanced EUV PelliclesCanatu Plc has received Site Acceptance Test (SAT) approval for its first CNT100 SEMI reactor and for the related post-processing peripherals, shipped to a semiconductor customer in September 2024. The equipment successfully passed the extensive tests conducted on-site at the customer's premises and met the stringent technical requirements and specifications defined in the acceptance criteria. This confirms the CNT100 SEMI reactor's readiness for mass production of CNT pellicle membranes. The next step for the customer is to secure final approval for the ready CNT pellicle product and the complete manufacturing line, before pilot and risk mass production can begin. This phase would initiate the mass production of CNT peLLicle membranes, generating non-recurring revenue from technology licensing, as well as recurring revenue from royalties on CNT pellicle sales, and from reactor consumables. Site Acceptance Test (Sat) means that the equipment is tested on-site after Factory Acceptance Test (FAT) to ensure the reactor and peripherals operate as intended in real use conditions. The SAT process included several output and product quality tests. With the SAT approval, Canatu's CNT100 SEMI reactor & peripherals are now ready for mass production. Demand for advanced semiconductors is accelerating due to the rapid growth of artificial intelligence. EUV (Extreme Ultraviolet) lithography is gaining traction, especially for sub-7 nanometer chips--the fastest-growing segment. Canatu is well-positioned to support this shift with its advanced CNT pellicle membranes, which perform traditional composite pellicles. These membranes offer higher EUV transmission and greater thermal resistance, enabling them to withstand the extreme heat loads of 600W EUV lithography tools used to produce the most advanced chips.
Board Change • May 21Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Director Tuomo Vahapassi is the most experienced director on the board, commencing their role in 2024. Independent Director Bernhard Stockmeyer was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 17Canatu Oyj Elects Anette Engelhardt as Member of the BoardCanatu Plc at its Annual General Meeting held on April 16, 2026 announced the election of Anette Engelhardt as a new member of the Board of the Directors until the end of the next Annual General Meeting.
お知らせ • Feb 11Canatu plc Appoints Antti Härmänmaa as Vice President, Legal and General Counsel, and Member of the Leadership Team, Effective 9 February 2026Canatu Plc has appointed Antti Härmänmaa as Vice President, Legal and General Counsel, and a member of the Leadership Team, effective 9 February 2026. The role is newly established and introduces Canatu's in-house legal function. In his role, Antti Härmänmaa is responsible for creating and leading Canatu's in-house legal function and providing legal counsel across the organization. His responsibilities cover legal, compliance, corporate governance, intellectual property rights, and contract matters. He will report to CEO Juha Kokkonen. Antti Härmänmaa (LL.M., Helsinki, New York University; eMBA, Aalto; b. 1979) brings extensive experience from senior legal leadership roles in international technology and media companies. He joins Canatu from Nokia Technologies, where he most recently served as Head of IP Legal and IP Business Services (2024-2026), following his role as Director, Legal & Compliance (2023-2024). Previously, Härmänmaa held senior legal leadership roles at Teosto (2017-2021) and at Sanoma (2008-2017). In addition, he serves as an Expert Member of the Market Court of Finland.
お知らせ • Jan 07Canatu Plc Announces Composition Of Shareholders' Nomination BoardCanatu Plc announced the composition of its Shareholders’ Nomination Board. The members of Canatu Plc’s Shareholders’ Nomination Board have been appointed. The composition of the Shareholders’ Nomination Board is the following: Ari Ahola (appointed by eFruit International Inc.), Denis Cherkasov (appointed by Mymetics Holding (Cyprus) Limited), Shinichiro Nakamura (appointed by DENSO Corporation), Tuomo Vähäpassi (appointed by Inventure Fund Ky). The Nomination Board elected Ari Ahola as Chair from among its members. In accordance with the Charter of the Shareholders’ Nomination Board, the Shareholders’ Nomination Board consists of four members, representing Canatu’s four largest shareholders, who held the largest number of votes in Canatu based on the shareholders’ register as per the situation on the first banking day of October 2025, considering the nominee-registered shares, and exercised their right of appointment. As the fourth largest shareholder Varma Mutual Pension Insurance Company did not exercise its right of appointment, the right was transferred to the fifth largest shareholder in accordance with the Charter of the Shareholders’ Nomination Board, Inventure Fund Ky, which appointed the fourth member of the Shareholder’s Nomination Board. The Chair of Canatu’s Board of Directors participates in the Shareholders’ Nomination Board’s work as an expert without having a right to participate in the decision-making of the Shareholders’ Nomination Board. The Shareholders’ Nomination Board is a corporate body appointed by Canatu’s shareholders that is responsible for preparing proposals to the annual general meeting, and if necessary, to the extraordinary general meeting, on the number, election, and remuneration of the members of the Board of Directors.
お知らせ • Aug 29+ 2 more updatesCanatu Oyj, Annual General Meeting, Apr 16, 2026Canatu Oyj, Annual General Meeting, Apr 16, 2026.
お知らせ • Jul 11Canatu plc Receives Customer Approval for its CNT100 SEMI Receptor and Post-Processing Equipment, Enabling Mass Production of Advanced EUV PelliclesCanatu Plc has received Site Acceptance Test (SAT) approval for its first CNT100 SEMI reactor and for the related post-processing peripherals, shipped to a semiconductor customer in September 2024. The equipment successfully passed the extensive tests conducted on-site at the customer's premises and met the stringent technical requirements and specifications defined in the acceptance criteria. This confirms the CNT100 SEMI reactor's readiness for mass production of CNT pellicle membranes. The next step for the customer is to secure final approval for the ready CNT pellicle product and the complete manufacturing line, before pilot and risk mass production can begin. This phase would initiate the mass production of CNT peLLicle membranes, generating non-recurring revenue from technology licensing, as well as recurring revenue from royalties on CNT pellicle sales, and from reactor consumables. Site Acceptance Test (Sat) means that the equipment is tested on-site after Factory Acceptance Test (FAT) to ensure the reactor and peripherals operate as intended in real use conditions. The SAT process included several output and product quality tests. With the SAT approval, Canatu's CNT100 SEMI reactor & peripherals are now ready for mass production. Demand for advanced semiconductors is accelerating due to the rapid growth of artificial intelligence. EUV (Extreme Ultraviolet) lithography is gaining traction, especially for sub-7 nanometer chips--the fastest-growing segment. Canatu is well-positioned to support this shift with its advanced CNT pellicle membranes, which perform traditional composite pellicles. These membranes offer higher EUV transmission and greater thermal resistance, enabling them to withstand the extreme heat loads of 600W EUV lithography tools used to produce the most advanced chips.
お知らせ • Jun 09+ 1 more updateCanatu plc Appoints Nedal Safwat as Chief Development Officer, and President of Canatu Inc, Effective June 9, 2025Canatu Plc announced the appointment of Dr. Nedal Safwat (PhD in Biochemistry) as Chief Development Officer, effective June 9, 2025. In his new role, Dr. Safwat will lead Canatu’s Medical Diagnostics business unit and serve as a member of the Management Team. Dr. Safwat brings over 20 years of industry expertise in medical diagnostics and a strong track record in business development across leading global organizations. Most recently, he served as Vice President, Portfolio and Program Management Office at Cepheid (2025). Before that, he served as the Vice President, Head of Molecular Diagnostics Sales and Marketing – North America at QIAGEN (2021–2024), and Vice President, Marketing and Business Development at ChromaCode Inc. (2020–2021). He also held multiple leadership roles in product development and commercial functions at bioMérieux (2009–2020).
